(Q46338578)

English

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

scientific article published on 30 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Joachim Stangier

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

Hildegard Stähle

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

Karin Rathgen

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

Willy Roth

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

Kasra Shakeri-Nejad

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

48

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

1411-1419

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Structure-based design of novel potent nonpeptide thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Clinical pharmacokinetics in patients with liver disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Drug administration in chronic liver disease

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Hepatic disease and drug pharmacokinetics

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Free drug concentration monitoring in clinical practice. Rationale and current status

1 reference

https://api.crossref.org/works/10.1177%2F0091270008324179

21 January 2018

Identifiers

10.1177/0091270008324179

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18827075

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46338578&oldid=2143926787"